April 14, 2016 8:38pm

 

A bumpy road with an uneven surface …

 

Do you care what happened today, you should because it has implications to tomorrow’s sector activity?   

Subscribe:  http://www.regmedinvestors.com/create-account   

 

Pre-open indication analysis – 3 hit and 1 miss

 

 

There is one thing that everyone needs, and that's interpretation and translation of intelligence, not just news or information - we get too much!

  • To that end, I report a matrix of variables designed for investor’s consideration concerning the stem, cell and gene therapy regenerative medicine portfolio to track and monitor its pricing metric;

The takeaway is that investor need to decide what actions to take, or not take, based on their specific situation.

 

 

U.S. stocks closed narrowly mixed Thursday. The Dow and S&P 500 squeezed out gains, with the Dow ending at its highest since July 20, 2015, and the S&P at its highest since Dec. 4. The NASDAQ ended less than 2 points lower.

The NASDAQ closed DOWN -1.53 or -0.03% to 4,945.98 and the DOW closed UP +18.15 or +0.10% to 17,926.43.

 

 

A day in the life of the stem, cell and gene therapy RegMed (SCGT & RM) sector – the advance/decline line scenario of our 43 covered companies.

  • Thursday, the stem, cell and gene therapy and regenerative medicine sector opened negative with an A/DL of 22/21 and 2 flats;
  • The mid-day moved positive with an A/DL of 27/14 with 2 flats;
  • The closing bell rang positive with A/DL of 25/16 with 2 flats

 

 

Henry’omics:

After a negative open, and then had a positive spurt to the mid-day and the sector closed positive.

  • The SCGT&RM sector moved higher having started lower after the programs had grabbed yesterday’s upside.

The constancy of a battle between the overbought versus the oversold continues - I had been expecting a number of shortfalls today but I believe there is reason to doubt that traders will stay long through this holiday weekend and worse no news or bad news is on the horizon.

 

 

Thursday’s handicapping the sector pre-open indications – 3 hit and 1 misses

  • Applied Genetic Technologies (AGTC) closed DOWN -$0.45 – hit;
  • Capricor (CAPR) closed UP +$0.07 – miss;
  • Intrexon (XON) closed UP +$2.37 – hit;
  • Spark Therapeutics (ONCE) closed DOWN -$0.07 – hit;

 

 

Out and about:

Osiris Therapeutics terminates Chief Medical Officer, Jon Hopper (OSIR).

  •  Mr. Hopper's responsibilities will be assumed by others with the Company's management team, including OSIR's Director of Regulatory Affairs and the Chief Scientific Officer. OSIR has undertaken a search for a potential replacement Chief Medical Officer.

 

 

Review my fear gauge or the CBOE Volatility Index (VIX):

  • Thursday below 14;
  • Wednesday traded below 14;
  • Tuesday traded near 15;
  • Monday traded above 16;
  • Friday traded near 15.4 – down!
  • Last, Thursday traded near 16.7;

 

 

Riding the indexes and ETFs roller-coaster:

  • The iShares Biotechnology Stocks ETF (IBB) closed UP on Thursday +0.43 or +0.15%
  • The NASDAQ Biotechnology index (NBI) closed UP +4.12 or +0.14%
  • The Russell 2000 (IWM) closed DOWN – 0.14 or -0.12%
  • The SPDR SD&P Biotech ETF (XBI) closed UP +0.34 or +0.60%

 

 

Who was leading the declines – to of the bottom 5?

  • Kite Pharma (KITE) closed down -$0.86 to $50.10;
  • bluebird bio (BLUE) closed down -$0.81 to $49.92;
  • Bellicum (BLCM) -$0.63 to $11.08;
  • Cellectis SA (CLLS) -$0.46 to $28.32;
  • Applied Genetic Technologies (AGTC) closed down -$0.45 to $16.72

 

 

Who was UP – top 5:

  • Intrexon (XON) +$2.31 to $38.00;
  • Organovo (ONVO) +$0.41 to $2.91;
  • Stemline (STML) +$0.26 to $5.72;
  • uniQure (QURE) +$0.23 to $13.02;
  • MiMedx (MDXG) closed up +$0.17 to $8.44

 

 

Most active sector stocks + and -:

  • Bellicum (BLCM) -5.38%;
  • BioLife Solutions (BLFS) -5.26%;
  • Opexa (OPXA) -3.92%;

Versus …

  • Organovo (ONVO) +16.40%;
  • Intrexon (XON) +6.74%
  • Neuralstem (CUR) +5.56%;

 

 

Who was FLAT?

  • Brainstorm (BCLI) at $2.29
  • ReNeuron (RENE.L) at $3.125

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.